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Abstracts / Osteoarthritis and Cartilage 20 (2012) S54–S296S128Purpose: Currently, there is no disease-modifying OA drug (DMOAD). We
have conceived that a strategy that achieves cartilage repair as well as
delays or stops OA progression may provide a better therapeutic solution.
Here we attempted to identify a new DMOAD candidate effective for both
repairing cartilage by promoting chondrogenic differentiation and halting
OA progression by suppressing aberrant hypertrophy. Then, we tested its
efﬁcacy as a DMOAD by injecting intraarticularly into mouse OA model
both at the onset of the model (preventionmodel) and at 4 weeks after the
onset (repair model). We further investigated the mechanism of the drug
action using in vitro and in vivo assays to investigate its molecular target.
Methods: We recently discovered a small thienoindazole-derivative
compound TD-198946 (TD), enhancing chondrogenic differentiation
without promoting hypertrophy using an efﬁcient monitoring system
expressing green ﬂuorescent protein under the control of type II collagen
promoter fused with four repeats of a Sox9 enhancer (COL2-GFP). Chon-
drogenic differentiation was assessed by real-time RT-PCR for Col2a1,
aggrecan, and Col10a1, Toluidine blue and Alcian blue stainings, and
quantitative GAG assay in immature mesenchymal C3H10T1/2 cells or
cultures of mouse primary chondrocytes. We injected TD intraarticulaly,
either immediately (prevention model) or 4 weeks (repair model) after OA
model surgery inmice. Knee joints were harvested at 8weeks after surgery
to examine the effects of TD on OA cartilage phenotypes using histology
and OARSI scores. The downstream molecules were screened by a micro-
array analysis using C3H10T1/2 cells. The COL2 promoter activity was
determined using HuH-7 cells transfected with a luciferase-reporter gene
construct containing the COL2 promoter above, and the speciﬁc binding to
the identiﬁed region was veriﬁed by electrophoretic mobility shift assay
(EMSA) and chromatin immunoprecipitation (ChIP). For functional anal-
yses, we performed adenoviral overexpression of the gene or the small
interfering RNA in C3H10T1/2 cells and primary chondrocytes, and
compared the chondrogenic differentiation as described above with
respective empty-vector controls. Finally, we analyzed molecular target
protein levels in OA human and mouse cartilage samples by
immunohistochemistry.
Results: TD was conﬁrmed to enhance chondrogenic differentiation but
not to promote hypertrophy. Intraartiluar TD treatment increased
proteoglycan abundance and decelerated articular cartilage degeneration,
and resulted in signiﬁcantly lower OARSI scores compared with saline
treatment in both of prevention and repair model. Themicroarray proﬁling
revealed that Runx1 was most strongly induced by TD among a set of the
196 transcription-related genes associated with the Gene Ontology term,
Multicellular organismal development. Deletion, mutagenesis, and
tandem-repeat analyses of the luciferase assay identiﬁed the core
responsive element of Runx1 in the COL2 promoter to be between the -293
and -288 bp region containing a putative Runx-binding motif. EMSA and
ChIP assays conﬁrmed the speciﬁc binding of Runx1 to this region.
Chondrogenic differentiation of C3H10T1/2 cells was enhanced by the
Runx1 overexpression without promoting hypertrophy in primary chon-
drocytes, simulating of the effect of TD treatment. Gene-silencing of Runx1
suppressed TD's effects on chondrogenic differentiation. Finally, in OA
human and mouse cartilage samples, Runx1 expression was suppressed,
and type10 collagen expression was overexpressed. Intraartiluar TD
treatment restored these protein expressions in mouse OA model. Overall,
these data suggest that TD's action is mediated by Runx1 in articular
chondrocytes.
Conclusions: These preclinical ﬁndings provide proof-of-concept for the
use of a novel small compound TD to treat OA.
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PROPERTIES AND USEFULNESS OF AGGREGATES OF SYNOVIAL
MESENCHYMAL STEM CELLS AS A SOURCE FOR CARTILAGE
REGENERATION
S. Suzuki, I. Sekiya, K. Tsuji, T. Muneta. Tokyo Med. and Dental Univ., Tokyo,
Japan
Purpose: Transplantation of mesenchymal stem cells (MSCs) derived from
synovium is a promising therapy for cartilage regeneration. For clinicalapplication, improvement of handling operation, enhancement of chon-
drogenic potential, and increase of MSCs adhesion efﬁciency are needed to
achieve a more successful cartilage regeneration with limited number of
MSCs without scaffold. The use of aggregated MSCs may be one of the
solutions. Here, we investigated the handling, properties, and effectiveness
of aggregated MSCs for cartilage regeneration.
Methods: Synovial MSCs. Human synovium was harvested from donors
during ACL reconstruction surgery. Rabbit synovium was harvested from
the knee joint. After collagenase digestion, nucleated cells were
expanded, and colony forming cells were harvested. Preparation of
aggregates of MSCs. 2.5105 synovial MSCs suspended in 35ml of culture
medium were aggregated using the hanging drop technique. Microarray
analysis. Total RNA was extracted from human synovial MSCs in
a monolayer culture, aggregates of human synovial MSCs cultured for 3
days. In vitro chondrogenic differentiation assay. 2.5  105 human syno-
vial MSCs cultured as monolayer were pelleted by trypsinization and
centrifugation. The pellets or aggregate of human synovial MSCs cultured
for 3 days in hanging drop were cultured in 400ml chondrogenic medium.
The medium was changed every 3-4 days for 21 days. Transplantation of
aggregates of synovial MSCs in rabbits. Osteochondral defects (55 mm
wide, 1.5 mm deep) were created in the femoral groove, and 5, 10, 20, 40,
80 aggregates of autologous synovial MSCs were transplanted to the
defect. MSCs labeled with DiI and MSCs derived from GFP rabbit were
also used. The cartilage was evaluated at 1 day, 2, 4, 12 weeks after the
operation (n ¼ 5). Statistical analysis. To assess differences, the Kruskal-
Wallis test and the Steel test were used. A P value of < 0.05 was
considered statistically signiﬁcant.
Results: Aggregates of MSCs cultured for three days became visible,
approximately 1mm in diameter, and solid and durable by manipulation,
and most of the cells were viable. Microarray analysis revealed upregula-
tion of chondrogenesis-related genes (SOX5, -6, -9, and BMP2) and anti-
inﬂammatory (TSG-6, and STC-1) genes in aggregates of MSCs. In vitro
studies showed higher amounts of cartilage matrix synthesis in pellets
derived from aggregates of MSCs compared to pellets derived from MSCs
cultured in a monolayer. In in vivo studies in rabbits, aggregates of MSCs
could adhere promptly on the osteochondral defects by surface tension,
and stay without any loss. Transplantation of aggregates of MSCs at rela-
tively low density achieved successful cartilage regeneration. Contrary to
our expectation, transplantation of aggregates of MSCs at high density
failed to regenerate cartilage due to apoptosis and nutrient deprivation of
aggregates of MSCs.
Conclusions: Aggregated synovial MSCs were a useful source for cartilage
regeneration considering such factors as easy preparation, higher chon-
drogenic potential, and efﬁcient attachment.
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SURGICAL IMPACTION AND INTRA-ARTICULAR ENVIRONMENT
PREDETERMINE SURVIVAL AND METABOLISM OF OSTEOCHONDRAL
ALLOGRAFTS
S. Gitelis, R. Olewinski, S. Kirk, A. Hakimiyan, L. Rappoport, C. Pacione,
B. Cole, M. Wimmer, S. Chubinskaya. Rush Univ. Med. Ctr., Chicago, IL, USA
Purpose: The purpose of this continuing study was to compare cellular
responses of cartilage from fresh (FOC) and refrigerated osteochondral
(ROC) allografts under the conditions mimicking intra-articular environ-
ment combined with surgically relevant impaction.
Methods: FOCs were obtained within 24 hours of death through the Gift of
Hope Organ & Tissue Donor Network (IL); ROCs were received from Joint
Restoration Foundation after 14-28 days refrigerated storage. 8mm
osteochondral plugs harvested from twelve ROC and six FOC were tapped
10 times with a peak force of 75N mimicking surgical insertion technique.
Samples were then cultured for up to 14 days in media containing 10% fetal
bovine serum and divided into the following treatment groups: 1) Non-
impacted control (serum only), 2) impacted non-treated control (serum
only), 3) impacted IL-1b (0.1ng/ml), 4) impacted IL-1b (0.1ng/ml) + IL-6
(3ng/ml), 5) impacted IL-1b (10ng/ml). IL-6 soluble receptor (5ng/ml) was
added to all cultures containing IL-6. The concentration of cytokines was
